Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9P278
UPID:
FNIP2_HUMAN
Alternative names:
FNIP1-like protein; O6-methylguanine-induced apoptosis 1 protein
Alternative UPACC:
Q9P278; Q05DC3; Q96I31; Q9H994
Background:
Folliculin-interacting protein 2, also known as FNIP1-like protein or O6-methylguanine-induced apoptosis 1 protein, plays a pivotal role in cellular response to amino acid availability. It regulates the mTORC1 signaling cascade, influencing the activity of MiT/TFE factors TFEB and TFE3. This protein is crucial in the lysosomal folliculin complex, affecting mTORC1 activity and autophagy through its interaction with GABARAP. Additionally, it serves as a co-chaperone of HSP90AA1/Hsp90, modulating its ATPase activity and client protein interaction.
Therapeutic significance:
Understanding the role of Folliculin-interacting protein 2 could open doors to potential therapeutic strategies.